Novartis International AG / Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.
- Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria
- Agreement is part of Novartis strategy to partner with like-minded innovators to further develop new medicines to address global health challenges
- Research and development for new medicines to treat tropical diseases continues through the Novartis Institute for Tropical Diseases
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.